Table 2.
Treatments and procedures during hospital admission. Values are percentages (numbers) unless stated otherwise
| Planned non-invasive | Planned invasive (n=13 408) | |||
|---|---|---|---|---|
| Ticagrelor (n=2601) | Clopidogrel (n=2615) | Total (n=5216) | ||
| Type of acute coronary syndrome* at discharge | ||||
| STEMI | 8.4 (218/2594) | 8.9 (233/2608) | 8.7 (451/5202) | 49.1 (6575/13 380) |
| NSTEMI | 55.6 (1441/2594) | 56.3 (1469/2608) | 55.9 (2910/5202) | 37.7 (5045/13 380) |
| Unstable angina pectoris or other | 36.0 (935/2594) | 34.7 (906/2608) | 35.4 (1841/5202) | 13.2 (1760/13 380) |
| Antithrombotic treatment during initial hospital admission | ||||
| Aspirin | 95.2 (2475/2600) | 94.7 (2472/2611) | 94.9 (4947/5211) | 98.0 (13 128/13 390) |
| Unfractionated heparin | 37.5 (975) | 36.7 (959) | 37.1 (1934) | 66.0 (8844) |
| Low molecular weight heparin | 64.1 (1668) | 63.6 (1663) | 63.9 (3331) | 47.1 (6318) |
| Fondaparinux | 5.0 (131) | 4.8 (125) | 4.9 (256) | 1.9 (253) |
| Bivalirudin | 0.3 (8) | 0.4 (10) | 0.3 (18) | 2.7 (356) |
| Glycoprotein IIb/IIIa inhibitor | 5.6 (145) | 6.2 (162) | 5.9 (307) | 35.3 (4730) |
| Other drug from randomisation to end of study | ||||
| β blocker | 85.0 (2212) | 83.9 (2194) | 84.5 (4406) | 85.7 (11 489) |
| ACE inhibitor/angiotensin receptor blocker | 83.2 (2162/2600) | 82.8 (2162/2611) | 83.0 (4324/5211) | 86.9 (11 637/13 390) |
| Cholesterol lowering drug (statin) | 89.9 (2337) | 89.7 (2345) | 89.8 (4682) | 95.3 (12 778) |
| Calcium antagonist | 29.5 (767) | 30.1 (786) | 29.8 (1553) | 21.7 (2905) |
| Diuretic | 48.9 (1272/2600) | 46.8 (1222/2611) | 47.9 (2494/5211) | 38.9 (5213/13 390) |
| Proton pump inhibitor | 39.9 (1038) | 39.0 (1020) | 39.5 (2058) | 54.0 (7237) |
| Invasive procedures | ||||
| Coronary angiography: | ||||
| Before discharge | 41.8 (1088) | 41.9 (1095) | 41.9 (2183) | 96.9 (12 987) |
| Any time during follow-up | 55.6 (1447) | 55.4 (1448) | 55.5 (2895) | 97.6 (13 085) |
| Median (IQR) time to angiography (hours) | 89 (26-266) (n=1445) | 92 (26-235) (n=1446) | 91 (26-240) (n=2891) | 0.6 (0.1-3.8) (n=13 083) |
| Percutaneous coronary intervention (PCI): | ||||
| Before discharge | 20.3 (528) | 20.5 (537) | 20.4 (1065) | 76.8 (10 298) |
| Any time during follow-up | 28.4 (738) | 29.7 (776) | 29.0 (1514) | 78.0 (10 463) |
| Median (IQR) time to PCI (hours) | 136 (40-379) (n=738) | 144 (42-391) (n=776) | 141 (41-383) (n=1514) | 0.8 (0.3-3.0) (n=10 462) |
| Coronary artery bypass grafting (CABG): | ||||
| Before discharge | 4.2 (108) | 3.8 (100) | 4.0 (208) | 5.7 (762) |
| Any time during follow-up | 11.0 (287) | 10.4 (272) | 10.7 (559) | 10.0 (1340) |
| Median (IQR) time to CABG (hours) | 609 (306-1682) (n=287) | 642 (308-1852) (n=272) | 623 (307-1742) (n=559) | 240 (92-1145) (n=1340) |
ACE=angiotensin converting enzyme; IQR=interquartile range; NSTEMI=non-ST segment elevation myocardial infarction; STEMI=ST segment elevation myocardial infarction.
*Defined by final diagnosis of index event.